Proteomic profiling in multiple sclerosis clinical courses reveals potential biomarkers of neurodegeneration

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Liguori, Maria ^a   Qualtieri, Antonio ^b   Tortorella, Carla ^c   Direnzo, Vita ^c   Bagalà, Angelo ^b   Mastrapasqua, Mariangela ^c   Spadafora, Patrizia ^b   Trojano, Maria ^c  

^a CNR   (Italy)

^b INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOGEN; FIBRINOPEPTIDE A; PROTEOME; SECRETOGRANIN II; SECRETOGRANIN V; THYMOSIN BETA4; BIOLOGICAL MARKER;

ADULT; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOLECULAR PATHOLOGY; MULTIPLE SCLEROSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; AGED; CEREBROSPINAL FLUID; CLINICAL TRIAL; MASS SPECTROMETRY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROTEOMICS;

ADULT; AGED; BIOLOGICAL MARKERS; FIBRINOGEN; FIBRINOPEPTIDE A; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84905454623     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0103984     Document Type: Article

References (46)

1. Comi G, Martinelli V, Rodegher M, Moiola L, Leocani L, et al. (2013) Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler 19: 1074-1083.
2. Nagtegaal GJ, Pohl C, Wattjes MP, Hulst HE, Freedman MS, et al. (2014) Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Mult Scler 20: 234-242.
3. Trojano M, Paolicelli D, Tortorella C, Iaffaldano P, Lucchese G, et al. (2011) Natural history of multiple sclerosis: have available therapies impacted long-term prognosis? Neurol Clin 29: 309-321.
4. Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC (2014) Onset of secondary progressive phase and long-term evolution of multiple sclerosis. J Neurol, Neurosurg Psychiatry 85: 67-75.
5. Zastepa E, Fitz-Gerald L, Hallett M, Antel J, Bar-Or A, et al. (2014) Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology 82: 681-690.
6. Schutzer SE, Angel TE, Liu T, Schepmoes AA, Xie F, et al. (2013) Gray matter is targeted in first-attack multiple sclerosis. PloS One 8: e66117.
7. Komori M, Matsuyama Y, Nirasawa T, Thiele H, Becker M, et al. (2012) Proteomic pattern analysis discriminates among multiple sclerosis-related disorders. Ann Neurol 71: 614-623.
8. Dhaunchak AS, Becker C, Schulman H, De Faria O Jr, Rajasekharan S, et al. (2012) Implication of perturbed axoglial apparatus in early pediatric multiple sclerosis. Ann Neurol 71: 601-613.
9. Le Pera M, Urso E, Sprovieri T, Bossio S, Aguglia U, et al. (2012) Contribution of cerebrospinal fluid thymosin beta4 levels to the clinical differentiation of Creutzfeldt-Jakob disease. Arch Neurol 69: 868-872.
10. Lublin FD, Reingold SC (1996) Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46: 907-11.
11. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, et al. (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58: 840-846. (Pubitemid 41746873)
12. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, et al. (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69: 292-302.
13. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1): 121-127.
14. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, et al. (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73: 1914-1922.
15. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231. (Pubitemid 13158528)
16. Tortorella C, Ruggieri M, Di Monte E, Ceci E, Iaffaldano P, et al. (2011) Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. J Neurol, Neurosurg Psychiatry 82: 1355-1359.
17. Teunissen C, Menge T, Altintas A, Alvarez-Cermeno JC, Bertolotto A, et al. (2013) Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. Mul Scler 19(13): 1802-1809.
18. Urso E, Le Pera M, Bossio S, Sprovieri T, Qualtieri A (2010) Quantification of thymosin beta(4) in human cerebrospinal fluid using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Biochem 402: 13-19.
19. Qualtieri A, Urso E, Le Pera M, Sprovieri T, Bossio S, et al. (2010) Proteomic profiling of cerebrospinal fluid in Creutzfeldt-Jakob disease. Exp Rev Proteomics 7: 907-917.
20. Anderson DR, Burnham KP, Gould WR, Cherry S (2001) Concerns about finding effects that are actually spurious. In: Biometrics, Wildlife Society Bullettin 29(1): 311-316.
21. Bender R, Lange S (2001) Adjusting for multiple testing - when and how? J Clin Epidemiol 54: 343-349. (Pubitemid 32303457)
22. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. Journal of the Royal StatisticalSociety Series B (Methodological) 57: 289-300.
23. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7: 115-121. (Pubitemid 32201673)
24. Filippi M, Rocca MA, Barkhof F, Bruck W, Chen JT, et al. (2012) Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 11: 349-360.
25. Kappos L, Achtnichts L, Dahlke F, Kuhle J, Naegelin Y, et al. (2005) Genomics and proteomics: role in the management of multiple sclerosis. J Neurol 252 Suppl 3: iii21-7. (Pubitemid 41355781)
26. International Multiple Sclerosis Genetics C, Wellcome Trust Case Control C, Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, et al. (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
27. Patsopoulos NA, Bayer Pharma MSGWG, Steering Committees of Studies Evaluating I-b, ANZgene Consortium, GeneMSA, et al. (2011) Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol 70: 897-912.
28. Disanto G, Handel AE, Damoiseaux J, Hupperts R, Giovannoni G, et al. (2013) Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients. Mult Scler 19: 1679-1680.
29. Verheul F, Smolders J, Trojano M, Lepore V, Zwanikken C, et al. (2013) Fluctuations of MS births and UV-light exposure. Acta Neurol Scand 127: 301-8.
30. Dagley LF, Emili A, Purcell AW (2013) Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis. Proteomics Clin Appl 7: 91-108.
31. Stoop MP, Singh V, Dekker LJ, Titulaer MK, Stingl C, et al. (2010) Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PloS One 5: e12442.
32. Comabella M, Fernandez M, Martin R, Rivera-Vallve S, Borras E, et al. (2010) Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis. Brain 133: 1082-1093.
33. Fischer-Colbrie R, Kirchmair R, Kahler CM, Wiedermann CJ, Saria A (2005) Secretoneurin: a new player in angiogenesis and chemotaxis linking nerves, blood vessels and the immune system. Curr Protein Pept Sci 6: 373-85. (Pubitemid 41052403)
34. Mattsson N, Ruetschi U, Podust VN, Stridsberg M, Li S, et al. (2007) Cerebrospinal fluid concentrations of peptides derived from chromogranin B and secretogranin II are decreased in multiple sclerosis. J Neurochem 103: 1932-1939. (Pubitemid 350126644)
35. Mattsson N, Johansson P, Hansson O, Wallin A, Johansson JO, et al. (2010) Converging pathways of chromogranin and amyloid metabolism in the brain. J Alzheimers Dis 20: 1039-1049.
36. Helwig M, Hoshino A, Berridge C, Lee SN, Lorenzen N, et al. (2013) The neuroendocrine protein 7B2 suppresses the aggregation of neurodegenerative disease-related proteins. J Biol Chemistry 288: 1114-1124.
37. Valis M, Talab R, Stourac P, Andrys C, Masopust J (2008) Tau protein, phosphorylated tau protein and beta-amyloid42 in the cerebrospinal fluid of multiple sclerosis patients. Neuro Endocrinol Lett 29: 971-6.
38. Mai W, Hu X, Lu Z, Peng F, Wang Y (2011) Cerebrospinal fluid levels of soluble amyloid precursor protein and beta-amyloid 42 in patients with multiple sclerosis, neuromyelitis optica and clinically isolated syndrome. J Int Med Res 39: 2402-2413.
39. Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA, et al. (2011) Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med 17: 568-573.
40. Davalos D, Ryu JK, Merlini M, Baeten KM, Le Moan N, et al. (2012) Fibrinogen-induced perivascular microglial clustering is required for the development of axonal damage in neuroinflammation. Nature Commun 3: 1227.
41. Gveric D, Hanemaaijer R, Newcombe J, van Lent NA, Sier CF, et al. (2001) Plasminogen activators in multiple sclerosis lesions: implications for the inflammatory response and axonal damage. Brain 124: 1978-1988. (Pubitemid 32945899)
42. Teunissen CE, Koel-Simmelink MJ, Pham TV, Knol JC, Khalil M, et al. (2011) Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. Mult Scler 17: 838-850.
43. Zhang J, Zhang ZG, Morris D, Li Y, Roberts C, et al. (2009) Neurological functional recovery after thymosin beta4 treatment in mice with experimental auto encephalomyelitis. Neuroscience 164: 1887-1893.
44. Mollinari C, Ricci-Vitiani L, Pieri M, Lucantoni C, Rinaldi AM, et al. (2009) Downregulation of thymosin beta4 in neural progenitor grafts promotes spinal cord regeneration. J Cell Sci 122: 4195-4207.
45. Morris DC, Zhang ZG, Zhang J, Xiong Y, Zhang L, et al. (2012) Treatment of neurological injury with thymosin beta4. Ann N Y Acad Sci 1269: 110-116.
46. Wirsching HG, Krishnan S, Florea AM, Frei K, Krayenbuhl N, et al. (2014) Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. Brain 137: 433-448.